The results from the Oncomine database showed that IGFBP2, IGFBP3, IGFBP4, and IGFBP5 were expressed at a higher level in tissues from patients with brain and CNS cancer than in normal tissues from healthy individuals. This evidence concerns the gene IGFBP5 and central nervous system cancer.